Central receipt of investigational product

Responsibility for the Investigational product (IP) rests with the investigator/institution, and the PI/institution may need to receive IP for several sites at a central location before they are allocated to individual sites. This procedure therefore describes the process for central receipt (i.e. at first place of receipt) of IP for a clinical trial, including placing it in quarantine and adding it to a pharmacy inventory. This procedure may be supplemented with a trial-specific pharmacy manual or process document(s) and additional procedures relating to receipt at field trial sites.